Interview: Jaime Malet – President, AmCham Spain
Jaime Malet, president of the US Chamber of Commerce (AmCham) in Spain, discusses the importance of the trade relations between the US and Spain, with eight percent of GDP made…
Company Description
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec’s significant products that address diseases such as multiple sclerosis (MS), lymphoma and rheumatoid arthritis. In 2008, Biogen Idec’s total revenues grew 29 percent over 2007 to $4.1 billion. Biogen Idec is headquartered in Cambridge, Massachusetts, with international headquarters in Zug, Switzerland. They have additional offices in the US, Canada, Australia, Japan and throughout Europe. Biogen Idec has a direct commercial presence in 29 markets, a network of distribution partners in more than 70 additional markets and operations in several new markets, including Central/Eastern Europe, Brazil, China and India.
Contact Info
Biogen Idec Iberia, S.L.
Paseo de la Castellana 41 – 3a
28046 Madrid
Spain
Phone: +34 91 310 71 10
Fax: +34 91 310 71 11
www.biogenidec.es
Jaime Malet, president of the US Chamber of Commerce (AmCham) in Spain, discusses the importance of the trade relations between the US and Spain, with eight percent of GDP made…
Carlos Teixeira, CEO of Teva Spain and Portugal, discusses the challenges the generic sector is facing in Spain, which ultimately spurred the company towards other business opportunities, and highlights the…
Eva Prada, director of the British Chamber of Commerce in Spain, discusses trade relations between the UK and Spain and the activities of the Chamber in developing trust-based business relationships…
Regina Múzquiz, director general of the Spanish Biosimilar Medicines Association (BioSim), discusses the importance of biosimilars as a tool to alleviate costs to the healthcare system and save EUR two…
Jose Escribano, founder of Spanish biotech success story ALGENEX, discusses the company’s focus on using insects in its research, difficulties in accessing capital, and its future growth strategy. Can you…
Jaume Pey, director general at the Spanish Association of Self-care (ANEFP), discusses the growth projections of the self-care segment in Spain, the impact that the ‘supresión del control previo sanitario’…
Concha Almarza, general manager at IQVIA Spain, discusses the changes that the Spanish pharmaceutical market has witnessed over the last few years, highlighting the stringent cost-containment measures aimed at improving…
Mariano Esteban Rodriguez, president of the Royal Academy of Pharmacy of Spain (RANF) and of the Institute of Spain (that integrates the 10 Royal Academies), discusses his current research interests…
Walther von Plettenberg, director of the German-Spanish Chamber of Commerce, discusses the strong relationship between the two countries and how Spain’s recent reforms puts the country at an economic advantage.…
Santiago de Quiroga, president editor of leading Spanish pharmaceutical industry newspaper El Global and CEO of healthcare communications group WeCare-u, discusses the country’s health priorities, highlighting the upcoming Personalized Medicine…
Humberto Arnés, director general at Farmaindustria, Spain’s leading pharmaceutical industry association, discusses the dynamics of the Spanish pharmaceutical industry showcasing a growth of 2.7 percent of the total public pharmaceutical…
Ion Arocena, CEO of ASEBIO, Spain’s biotech association, discusses the significant efforts that Spain has made in turning cutting-edge research into successful companies and products and provides an insight into…
See our Cookie Privacy Policy Here
